CHNC China Infrastructure Construct

CHNC Ventures Into Latin American Country for Extension of Its Clinical Research Facilities

CHNC Ventures Into Latin American Country for Extension of Its Clinical Research Facilities

HOUSTON, TX, Oct. 25, 2021 (GLOBE NEWSWIRE) -- via – China Infrastructure Construction Corp. (OTC: CHNC) (dba Cannabis Bioscience International Holdings) announces the expansion of its clinical research services to Latin America with a new agreement/alliance with QUIASMO, an IPS medical clinic based in Bogotá, Colombia. 

“Not only has Alpha Research Institute expanded the services offered to Puerto Rico, but it is our pleasure to announce that we have also signed a contract with a clinic in Bogota, Colombia that will serve as an extension for Alpha in Latin America. QUIASMO is a medical clinic with a wide range of services that cover infectiology, family medicine, general medicine, nutrition, psychology, nursery and sample collection,” says Anne Graham, CHNC’s CLO.

The interdisciplinary team of highly qualified professionals of the clinic is led by Dr. John Jairo Carvajal, with a Master’s degree in HIV Management. As well, Dr. Carvajal possesses great knowledge in the integral comprehensive care of catastrophic pathologies. His expertise, alongside the technology and equipment available, allows this health clinical center to properly adapt to the design and structure of many investigation projects.

This is a logical step for CHNC in the right direction. “In order for us to grow as a company, we need to continue to expand to International Markets and identify new areas where we can share our knowledge,” adds Dr. Deepika Deol, Alpha Research Institute Clinical Director.

CHNC expects to meet the needs of big pharmaceutical companies looking to perform clinical investigations in Latin American countries with this new medical attention center in Colombia. Expanding the grasp of our services into the Colombian market will allow us to provide its community with life-changing treatments and scientific development in a wide range of therapeutic areas. 

To learn more visit:  

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

For more information contact us at:



817/528-2475 for English

214/733-0868 for Spanish



EN
25/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Infrastructure Construct

 PRESS RELEASE

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassific...

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification HOUSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CBIH is proud to announce that Brian Cuban, Esq., a distinguished attorney, best-selling author, mental health advocate, and esteemed member of our Advisory Board, has officially joined the Reclassification Team. Mr. Cuban will play a crucial role in representing CBIH at the upcoming DEA hearings on marijuana rescheduling. Brian Cuban, the younger brother of entrepreneur Mark Cuban, brings a unique combination of personal recovery experience and professional advocacy to ...

 PRESS RELEASE

Cannabis Bioscience International Holdings (CBIH) Announces Partnershi...

Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products HOUSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to announce a groundbreaking partnership with Stephen Gould, marking a monumental step forward in the manufacturing and distribution of CBIH’s advanced medical product line. This collaboration represents a shared commitment to excellence and innovation in the healthcare industry. Stephen Gould, a company with a remarkable presence...

 PRESS RELEASE

CBIH Files Petition to Include Alexis Bortell as Witness in DEA Resche...

CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing HOUSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (CBIH) continues its unwavering advocacy for cannabis as a legitimate medicine by formally petitioning to have Ms. Alexis Bortell, long-time cannabis advocate and patient, to serve as a witness in the upcoming DEA hearing on marijuana rescheduling. Alexis Bortell has been a leading voice in the fight for medical cannabis access since being diagnosed with intractable epilepsy at the age of seven. After enduring years...

 PRESS RELEASE

A Letter from the Desk of CBIH

A Letter from the Desk of CBIH HOUSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings Dear Community, On Monday, December 2, I had the honor of representing Cannabis Bioscience International Holdings (CBIH) at the DEA Hearing Docket No. 1362 and Hearing Docket No. 24-44, focused on the reclassification of cannabis. Being chosen to speak on behalf of not only our company but also medicine, science, and patients is a privilege and a profound responsibility. CBIH remains committed to activ...

 PRESS RELEASE

CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hear...

CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hearing HOUSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) proudly announces its active participation in today’s DEA meaningful hearing on cannabis reclassification. Representing CBIH at this critical event in Arlington, Virginia, is Dante Picazo, the company’s esteemed Director and CEO, bringing years of expertise and leadership in the medical cannabis industry to Docket No. 1362, Hearing Docket No. 24-44. Mr. Picazo has presented a comprehensive 78-page statement that un...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch